Trials / Unknown
UnknownNCT02695550
Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Centaurus Biopharma Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I study of the ALK/FAK/Pyk2 inhibitor CT-707 in patients with ALK-positive non-small cell lung cancer. The purpose of the study is to determine the MTD/RP2D of CT-707 and evaluate whether CT-707 is safe and has beneficial effects in ALK-positive advanced non-small cell lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CT-707 |
Timeline
- Start date
- 2016-03-01
- Primary completion
- 2018-03-01
- Completion
- 2018-03-01
- First posted
- 2016-03-01
- Last updated
- 2017-03-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02695550. Inclusion in this directory is not an endorsement.